Acute Gout — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Acute gout attacks manifest swiftly, reaching peak joint pain within 24 hours. Remission usually begins within 5 to 12 days without intervention, but complete resolution may take longer. Most attacks are monoarticular, with the first metatarsophalangeal joint being the initial site in approximately 50% of cases. While the pain typically peaks within 24 hours, chronic or variable intensity pain is more prevalent in patients with long-standing disease. Gout treatment involves addressing the pain and inflammation of acute attacks and long-term management focused on lowering serum urate levels. Gout patients, often older with multiple comorbidities, face challenges due to accompanying health conditions like diabetes and cardiovascular disease. Diagnosing gout relies on clinical signs, including sudden pain onset, past arthritis attacks, first MTP involvement, and elevated serum urate. However, not all criteria must be present. The ACR recommends pharmacologic therapy as the primary approach for acute gout attacks, with options like NSAIDs, colchicine, or systemic glucocorticoids. Monotherapy is suitable for mild-to-moderate pain affecting ≤ 2 joints, while severe pain or attacks involving multiple joints may benefit from initial combination therapy. Systemic glucocorticoids are commonly used in acute gout treatment.
- Approximately 9.2 million people in the United States, constituting about 3.9% of the adult population, are affected by gout.
Thelansis’s “Acute Gout Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Gout treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Acute Gout across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Acute Gout Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
